LOS ANGELES, Dec. 23, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Integer Holdings Corporation (“Integer” or “the Company”) (NYSE: ITGR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between July 25, 2024 and October 22, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before February 9, 2026.

image for news ITGR Investors Have Opportunity to Lead Integer Holdings Corporation Securities Fraud Lawsuit with the Schall Law Firm

POET Technologies is upgraded from Hold to Buy due to the Marvell-Celestial AI deal, highlighting POET's strategic importance in AI data center infrastructure. POET's technology is a key enabler of Celestial AI's Photonic Fabric platform, positioning it as a strategic supply chain partner. Marvell's acquisition of Celestial AI indirectly validates POET's technology and increases the likelihood of POET being targeted for acquisition by a major IT player.

image for news POET Technologies: Is It The Next Takeover Target After Marvell's Celestial AI Deal?

SAN DIEGO, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Stride, Inc. (NYSE: LRN) securities between October 22, 2024 and October 28, 2025, both dates inclusive (the “Class Period”), have until Monday, January 12, 2026 to seek appointment as lead plaintiff of the Stride class action lawsuit. Captioned MacMahon v.

image for news LRN INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Stride, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit

Bristol-Myers Squibb Surges Into Year-End: Why BMY Still Looks Undervalued — Positive

BMY   Seeking Alpha — December 23, 2025

Bristol-Myers Squibb remains a "Buy," driven by robust Q3 results and a positive technical setup heading into 2026. BMY raised FY 2025 guidance, with operating EPS targeted at $6.40–$6.60 and net sales above consensus, reflecting pipeline strength. Shares trade at a discount to peers with a 14% FCF yield, while multiple late-stage drugs and recent acquisitions support long-term growth.

image for news Bristol-Myers Squibb Surges Into Year-End: Why BMY Still Looks Undervalued

Close To 7% Investment-Grade Opportunity: W. R. Berkley's Baby Bonds — Positive

WRB   Seeking Alpha — December 23, 2025

W. R. Berkley Corporation maintains solid investment-grade credit ratings and a strong balance sheet with $43.7B in assets and $3.08B in debt. WRB's baby bonds, all investment-grade, currently trade below par with yields to worst around 7%, offering attractive risk-adjusted returns. WRB has delivered robust long-term total returns: 20.8% over 5 years and 17% over 10 years, outperforming insurance sector benchmarks.

image for news Close To 7% Investment-Grade Opportunity: W. R. Berkley's Baby Bonds

AJG Stock Trading at a Discount to Industry at 2.85X: Time to Hold? — Positive

AJG   Zacks Investment Research — December 23, 2025

Arthur J. Gallagher stock gains on the back of strategic acquisitions, solid retention and improving renewal premiums, as well as financial flexibility.

image for news AJG Stock Trading at a Discount to Industry at 2.85X: Time to Hold?

Walmart's Ad Sales Jump 53%: Is Advertising Becoming a Profit Engine? — Positive

WMT   Zacks Investment Research — December 23, 2025

WMT's ad revenues surge 53% in Q3, with retail media and data-driven ads lifting margins and reshaping its profit mix.

image for news Walmart's Ad Sales Jump 53%: Is Advertising Becoming a Profit Engine?

Novo Nordisk vs. Amgen: Which Healthcare Stock Is the Smarter Choice? — Positive

AMGN  NVO   Zacks Investment Research — December 23, 2025

NVO and AMGN square off as GLP-1 leadership, pipeline depth, and diversification set up a compelling healthcare stock comparison.

image for news Novo Nordisk vs. Amgen: Which Healthcare Stock Is the Smarter Choice?

Q3 GDP +4.3%: Consumer Carries Economic Heft — Positive

DIA  GDP  QQQ  SPY   Zacks Investment Research — December 23, 2025

Q3 GDP posted its strongest growth number in two years, and half a point higher than Q2's +3.8%.

image for news Q3 GDP +4.3%: Consumer Carries Economic Heft

Best Momentum Stocks to Buy for Dec. 23 — Positive

IAG  SU  VLO   Zacks Investment Research — December 23, 2025

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, Dec. 23:

image for news Best Momentum Stocks to Buy for Dec. 23

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Firefly Aerospace To Contact Him Directly To Discuss Their Options If you purchased or otherwise acquired: (a) Firefly common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company's initial public offering conducted on or about August 7, 2025 (the "IPO" or "Offering"); and/or (b) Firefly securities between August 7, 2025 and September 29, 2025, both dates inclusive (the "Class Period") and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at …

image for news SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Announces that Firefly Aerospace Investors Have Opportunity to Lead Class Action Lawsuit

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Rezolute To Contact Him Directly To Discuss Their Options If you suffered significant losses in Rezolute stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , Dec. 23, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Rezolute, Inc. ("Rezolute" or the "Company") (NASDAQ: RZLT).

image for news INVESTIGATION NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Bitdeer To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Bitdeer between June 6, 2024 and November 10, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , Dec. 23, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Bitdeer Technologies Group ("Bitdeer" or the …

image for news SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bitdeer Technologies

TSLA Soars: Cautious Bearishness & Options Play — Positive

TSLA   Schwab Network — December 23, 2025

Tesla (TSLA) stock soared over 20% in 2025, reaching new highs. Marley Kayden highlights a raised price target from Canaccord Genuity, despite a reduced Q4 delivery outlook, noting the market's focus beyond near-term challenges.

image for news TSLA Soars: Cautious Bearishness & Options Play

Needham & Co. boosts its price target on Rocket Lab's stock to $90 from $63.

image for news Rocket Lab Stock Has Been a December Darling. It Has More Room to Rise, Say Analysts.

Coherus Oncology: A Two-Pronged March With Mid-2026 Implications — Positive

CHRS   Seeking Alpha — December 23, 2025

Coherus Oncology maintains a 'Buy' rating, driven by a promising clinical pipeline and undervaluation relative to cash and equity holdings. CHRS's commercial growth is anchored by toripalimab sales in a niche U.S. indication, but profitability hinges on pipeline success. Key catalysts include mid-2026 data readouts for casdozokitug and CHS-114; no major Q1 2026 milestones are expected.

image for news Coherus Oncology: A Two-Pronged March With Mid-2026 Implications

Can Cloudflare's Edge AI Inference Reshape Cost Economics? — Positive

NET   Zacks Investment Research — December 23, 2025

NET's edge AI inference bets on efficiency over scale, using custom Rust-based Infire to boost GPU use, cut latency, and reshape inference costs.

image for news Can Cloudflare's Edge AI Inference Reshape Cost Economics?

Stormy 2026? 3 Defensive Stocks to Weather a Recession — Neutral

JNJ  NEE  TPB   Zacks Investment Research — December 23, 2025

TPB, JNJ and NEE highlight how defensive stocks can offer stability and steady growth potential amid rising uncertainty for 2026.

image for news Stormy 2026? 3 Defensive Stocks to Weather a Recession

NVTS Leans on Strategic Partnerships: Will This Fuel Long-Term Growth? — Positive

NVTS   Zacks Investment Research — December 23, 2025

Navitas Semiconductor is doubling down on strategic partnerships to strengthen its global reach and prepare for scaling in high-power markets.

image for news NVTS Leans on Strategic Partnerships: Will This Fuel Long-Term Growth?

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Freeport-McMoran To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Freeport between February 15, 2022 and September 24, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , Dec. 23, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Freeport-McMoran Inc. ("Freeport" or the "Company") …

image for news SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Announces that Freeport-McMoran Systems Investors Have Opportunity to Lead Class Action Lawsuit